The Uncomfortable Truth About Alternative Therapies.
Exploring Why Promising Natural Therapies Like Ivermectin and Iodine Lack Large Scale Research Despite Growing Evidence
For years, at Holistic GoCancerGo, we've explored numerous holistic, natural, and integrative approaches alongside conventional medicine. Not because we have all the answers, but because we have faced many with serious illness, and we begin asking better questions.
One persistent observation has troubled us: There's a growing body of information, research, and human stories around certain alternative therapies, yet remarkably few large scale human trials are done. The uncomfortable truth, in our opinion, is that many of these options simply aren't profitable. No patent. No ownership. No long-term revenue stream. So the funding never comes, and without funding, the trials never happen.
Consider this: What if the most promising cancer therapies aren't being researched because they can't be patented? What if patients are being denied potentially life-saving options simply because those options aren't profitable? The current research model prioritizes profit over potential, leaving millions to rely on anecdotal evidence when conventional medicine has "run out of road."
The modern medical research ecosystem is built on a fundamental economic reality: Research costs money, and investors expect returns. Pharmaceutical companies typically invest $2-3 billion to bring a new drug to market. They recoup these costs through patent protection, which grants exclusive marketing rights for 20 years. But what happens when a therapy can't be patented?
Originally developed for parasites, this Nobel Prize-winning drug shows anti-inflammatory, anti-viral, and potential anti-cancer properties in preliminary studies, yet lacks large-scale cancer trials
Essential nutrient with documented anti-cancer effects in breast, prostate, and ovarian tissues, but as a naturally occurring element, it cannot be patented for therapeutic use
Without patent protection, there's no financial incentive for pharmaceutical companies to invest in the expensive clinical trials required for FDA approval and mainstream acceptance
Mounting anecdotal evidence and small studies exist, but without large-scale trials, these therapies remain in the realm of "alternative" rather than "evidence-based" medicine
Of the National Cancer Institute's annual $6 billion budget is allocated to studying complementary and alternative medicine approaches, despite growing public interest and use.
The Critical Insight: The current system creates a perverse incentive structure. A company could spend hundreds of millions proving that an unpatentable substance works, only to have competitors immediately sell the same substance. This economic reality, not scientific merit, determines what gets studied and what gets ignored.
| Therapy Type | Patent Status | Average Trial Cost | Financial Incentive | Research Status |
|---|---|---|---|---|
| New Chemical Drug | Patentable | $2-3 Billion | High | Extensively studied |
| Natural Compound (e.g., Curcumin) | Partially Patentable | $500M-1B | Moderate | Moderately studied |
| Generic Drug Repurposing (e.g., Ivermectin) | Off-Patent | $300-500M | Low | Minimally studied for new uses |
| Essential Nutrient (e.g., Iodine, Vitamin C) | Unpatentable | $200-400M | None | Rarely studied for therapeutic doses |
| Herbal Preparation | Difficult to Patent | $100-300M | Very Low | Anecdotal evidence only |
â ïž The Human Cost: This profit driven research model means that when conventional medicine declares a patient "inoperable" or "terminal," they're often left with no "evidence based" options, despite the existence of promising alternatives that simply haven't been studied due to lack of financial incentive.
While large scale human trials are lacking for many alternative therapies, that doesn't mean evidence is completely absent. Let's examine what we do know about the two examples mentioned:
Mechanisms of Action Relevant to Cancer:
Research Status: While no large-scale human cancer trials exist, numerous in vitro and animal studies show promising results against breast, ovarian, colon, and other cancers. A 2020 review in the Journal of Clinical Medicine noted: "Ivermectin demonstrates broad-spectrum anti-tumor activity through multiple mechanisms."
Historical and Modern Evidence:
The Research Gap: Despite this evidence, there have been no large-scale randomized controlled trials investigating high-dose iodine as a cancer therapy. The nutrient is generally recognized as safe, but therapeutic applications remain unexplored in formal trials.
"The absence of evidence is not evidence of absence. Just because a therapy hasn't been studied in large, expensive trials doesn't mean it doesn't work. It often means there's no profit in studying it."
- Dr. John Campbell, discussing research biases in medical science
We recently watched this video of Dr. John Campbell, which touches on many of these points far better than we can in writing. If you have an open mind, we encourage you to watch it:
When someone is classified as inoperable, terminal, and given a short life expectancy, why not be honest and say: "This may not work, but neither has what we've tried so far. Here are some other avenues you could explore if you choose." It won't work for everyone, but neither does conventional Western treatment.
Surely at that point, a person deserves the chance to take a leap of faith, to feel empowered rather than written off. We're slowly seeing a shift toward integrating other options with conventional Western treatments, but progress is painfully slow.
Terminal patients deserve access to all potential options, not just those that have passed through the profit-driven research pipeline
Patients should receive complete information about both conventional and alternative options, including the limitations of the evidence for each
When facing terminal illness, individuals should have the right to make their own risk-benefit calculations about unproven therapies
The best approach often combines conventional and alternative methods, yet this integrated model is rarely discussed or offered
These stories aren't presented as proof of efficacy, but as evidence of human resilience and the need for a more flexible, compassionate approach when conventional options fail.
The current profit-driven research model fails patients when it comes to unpatentable therapies. But several potential solutions could create a more equitable, patient-centered research ecosystem:
Government and non-profit organizations should fund trials for promising but unprofitable therapies, treating this research as a public health investment
Patients could pool resources to fund research on therapies that matter to them, bypassing the profit requirement altogether
Systematically collecting and analyzing outcomes from patients using alternative therapies could build evidence without expensive trials
Creating alternative approval pathways for repurposed drugs and natural compounds could reduce costs and encourage research
Estimated cost of conducting trials for repurposed drugs versus new drugs, since safety data already exists. This makes publicly funded trials more feasible.
At Holistic GoCancerGo, we're committed to:
We're not here to tell anyone what to do. We're sharing our experiences and asking questions we think matter. We'd genuinely love to hear your thoughts:
Share your thoughts under the SHARE link and let us know if we can publish them (with anonymity if preferred).
Something to Share?Holistic GoCancerGo operates independently of pharmaceutical funding or corporate interests. Our mission is to provide balanced education / information about Holistic, integrative and Natural cancer care options. Your support helps us continue this important work and save lives.
Learn About Our Mission Share Your Story